{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to assess the usage pattern of aripiprazole in the management of schizophrenia in India

Survey Questionnaire Form
Doctor’s details
@if(isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of schizophrenia do you see in a month? *

  2. In your clinical practice, what percentage of your total patient population are diagnosed with schizophrenia? *

  3. In your clinical practice schizophrenia is more commonly found in? *

  4. In your clinical experience, schizophrenia is more commonly diagnosed in which age group of patients? *

  5. How often do you encounter first-episode of schizophrenia in your practice? *

  6. What are the most common positive symptoms observed in your patients with schizophrenia? *

  7. What are the most common negative symptoms observed in your patients with schizophrenia? *

  8. As per your clinical experience, which factors are critical for choosing first-line treatment option in the management of schizophrenia? *

  9. How frequently do you prescribe Aripiprazole for schizophrenia patients in your clinical practice? *

  10. What is the usual starting dose of Aripiprazole in your practice for treatment of schizophrenia? *

  11. What factors influence your decision to prescribe Aripiprazole over other antipsychotics for schizophrenia? *

  12. How effective is Aripiprazole in managing positive symptoms of schizophrenia according to your experience? *

  13. How effective is Aripiprazole in managing negative symptoms of schizophrenia according to your practice? *

  14. What is the typical duration of Aripiprazole treatment for acute schizophrenia episodes in your patients? *

  15. Do you use Aripiprazole as monotherapy or in combination with other medications for schizophrenia management? *

  16. What percentage of your schizophrenia patients currently take aripiprazole? *

  17. What is your approach for managing metabolic side effects associated with Antipsychotics? *

  18. Do you prefer Aripiprazole in specific subtypes of schizophrenia (e.g., treatment-resistant, first episode)? *

  19. How often do you switch patients from other antipsychotics to Aripiprazole due to inadequate response or intolerable side effects? *

  20. What is your preferred augmentation strategy if Aripiprazole monotherapy is insufficient for symptom control? *

  21. What is your preferred monitoring interval for patients on Aripiprazole for schizophrenia? *

  22. How frequently do you combine psychotherapy with Aripiprazole treatment in schizophrenia patients? *

  23. What is your preferred method for assessing treatment response to Aripiprazole in schizophrenia? *

  24. What are the most common reported patient concerns regarding use of antipsychotic therapy? *

  25. How do you educate patients about potential side effects and benefits of Aripiprazole therapy? *

  26. Mention some initial instructions/advice you give to your patients before initiating the aripiprazole for the treatment of schizophrenia *

  27. How often do you encounter medication non-adherence among your patients with schizophrenia? *

  28. What factors do you find most commonly contribute to medication non-adherence in schizophrenia patients? *

  29. What is your preferred approach to addressing medication non-adherence in schizophrenia patients? *

  30. What are your thoughts on the overall tolerability and efficacy of Aripiprazole compared to other antipsychotics in the management of schizophrenia? *